M. Dómine Gómez

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

N. Reguart, B. Massuti, V. Calvo, 2021, Molecular oncology.

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

G. Giaccone, E. Felip, L. Paz-Ares, 2019, European Journal of Cancer.

OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC

E. Schmidt, E. Felip, H. Gabra, 2021 .

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

A. Navarro, R. Huber, M. Thomas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.

T. Owonikoko, P. Roberts, J. Hamm, 2019 .

Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer

J. Subramanian, D. Radosavljevic, T. Csoszi, 2021, International Journal of Cancer.

973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC

P. Schwarzenberger, J. Gray, M. Reck, 2022, Annals of Oncology.

Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting

Susana Traseira Lugilde, B. Cantos Sánchez de Ibargüen, I. Peláez Fernández, 2016, Advances in Therapy.

SEOM clinical guidelines for the treatment of small-cell lung cancer

D. Isla Casado, R. García Campelo, Á. Artal Cortés, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

SEOM clinical guidelines for the treatment of small-cell lung cancer 2013

Á. Artal Cortés, M. Dómine Gómez, T. Moran Bueno, 2013, Clinical and Translational Oncology.

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

J. R. Jarabo Sarceda, A. Martínez-Martí, R. Bernabé Caro, 2024, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.